Evidence map›Paper›PMID 36193631›Full record

ArticleBiochemistry2022

Kinetic Characterization and Inhibition of

Kayla Glockzin, Demetrios Kostomiris, Yacoba V T Minnow, Kajitha Suthagar, Keith Clinch, Sinan Gai, Joshua N Buckler, Vern L Schramm, Peter C Tyler, Thomas D Meek and 1 more

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. ACS omega · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Inhibition and Mechanism ofACS chemical biology · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Kayla GlockzinDepartment of Biochemistry and Biophysics, Texas A&M University, 300 Olsen Boulevard, College Station, Texas 77843-2128, United States.ORCID 0000-0003-2406-532X
Demetrios KostomirisDepartment of Biochemistry and Biophysics, Texas A&M University, 300 Olsen Boulevard, College Station, Texas 77843-2128, United States.
Yacoba V T MinnowDepartment of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461-1602, United States.
Kajitha SuthagarFerrier Research Institute, Victoria University of Wellington, Gracefield Research Centre, 69 Gracefield Road, Gracefield, Lower Hutt 5010, New Zealand.
Keith ClinchFerrier Research Institute, Victoria University of Wellington, Gracefield Research Centre, 69 Gracefield Road, Gracefield, Lower Hutt 5010, New Zealand.
Sinan GaiFerrier Research Institute, Victoria University of Wellington, Gracefield Research Centre, 69 Gracefield Road, Gracefield, Lower Hutt 5010, New Zealand.
Joshua N BucklerFerrier Research Institute, Victoria University of Wellington, Gracefield Research Centre, 69 Gracefield Road, Gracefield, Lower Hutt 5010, New Zealand.ORCID 0000-0002-4397-9947
Vern L SchrammDepartment of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461-1602, United States.ORCID 0000-0002-8056-1929
Peter C TylerFerrier Research Institute, Victoria University of Wellington, Gracefield Research Centre, 69 Gracefield Road, Gracefield, Lower Hutt 5010, New Zealand.ORCID 0000-0002-3151-6208
Thomas D MeekDepartment of Biochemistry and Biophysics, Texas A&M University, 300 Olsen Boulevard, College Station, Texas 77843-2128, United States.
Ardala KatzfussDepartment of Biochemistry and Biophysics, Texas A&M University, 300 Olsen Boulevard, College Station, Texas 77843-2128, United States.ORCID 0000-0002-7177-9600
Victoria University of Wellington · NZTexas A&M University · USAlbert Einstein College of Medicine · US

Funding

TRANSITION STATE ANALYSIS OF ENZYMATIC REACTIONSR01GM041916 · NIGMS · YESHIVA UNIVERSITY · PI SCHRAMM, VERN L. · 1989 to 2023
$10.0M
PROTOZOAN PURINE PHOSPHORIBOSYLTRANSFERASES AS TARGETS TO TREAT MALARIA, AFRICAN TRYPANOSOMIASIS AND CHAGAS'S DISEASER01AI127807 · NIAID · TEXAS A&M AGRILIFE RESEARCH · PI MEEK, THOMAS, SCHRAMM, VERN L. · 2017 to 2021
$5.2M
NIAID NIH HHS R01 AI127807NIGMS NIH HHS R01 GM041916
6 · The paper itself

Abstract

Chagas disease, caused by the parasitic protozoan

Indexed as

Chagas DiseaseTrypanosoma cruziAntiparasitic AgentsGuanineGuanosine MonophosphateHumansHypoxanthine PhosphoribosyltransferaseInosine MonophosphateIsoenzymesPurinesAntiparasitic AgentsGuanineGuanosine MonophosphateHypoxanthine PhosphoribosyltransferaseInosine MonophosphateIsoenzymesPurines

Identifiers

PMID36193631
PMCPMC9536471
OpenAlexW4296127109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.